Pigmented villous synovitis (PVS) is a rare and complex joint disease characterized by inflammation of the synovial membrane with the formation of pigmented villi, which can lead to functional impairment and significant discomfort. This pathology most often occurs in the knee and elbow joints, but can sometimes affect other joints. PVS refers to a group of chronic inflammatory diseases, by its nature includes both autoimmune and metabolic mechanisms, which complicates diagnosis and determination of the exact causes of occurrence. The mechanisms of disease development include activation of macrophages and increased synthesis of the extracellular matrix in response to various pathogenic factors.
History of the disease and interesting historical facts
Pigmented villous synovitis was first described in the medical literature in the mid-20th century. One of the first researchers to pay attention to the characteristics of the disease was a well-known orthopedic surgeon, who distinguished this disease from other forms of synovitis due to its characteristic clinical manifestations and microscopic examination features. Historically, PVS was often mistaken for other forms of synovitis, such as traumatic or infectious. There are publications linking the onset of the disease with professions associated with prolonged physical exertion and low temperatures, which historically confirms the position on the relationship between lifestyle and health. In recent decades, researchers have emphasized the importance of early diagnosis and intervention, which significantly improves treatment outcomes.
Epidemiology
According to medical statistics, pigmented villous synovitis is a relatively rare disease. Its prevalence is approximately 0.5 per 100,000 population. In most cases, PVS is diagnosed in people aged 30 to 60 years, with men and women suffering equally. Research data show that patients with PVS have concomitant autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, which may indicate a potential interaction between these conditions. Due to improvements in imaging methods and laboratory diagnostics of joint diseases, cases of PVS have become more common, which has certainly affected the statistics.
Genetic predisposition to this disease
Current research suggests that genetic predisposition may play an important role in the development of pigmented villous synovitis. Certain genes, such as HLA-DRB1 and other regions associated with the immune response, may influence the likelihood of developing the disease. People with certain polymorphisms in these genes are more likely to develop PVS. In addition, mutations that regulate inflammation may also increase susceptibility to the disease. Genetic research is still in progress, with the aim of identifying specific markers that can predict the risk of developing PVS in individuals who already have associated diseases.
Risk factors for the development of this disease
Risk factors for pigmented villous synovitis include both physical and chemical influences that may contribute to its development. The main risk factors are:
- Frequent joint injuries, especially in athletes or people engaged in heavy physical labor.
- Preexisting medical conditions such as osteoarthritis, rheumatoid arthritis or systemic lupus.
- In addition, environmental factors such as prolonged exposure to cold and damp environments.
- Certain chemicals, such as heavy metals, can accumulate in the body and affect internal processes.
In recent years, emphasis has also been placed on psychosocial factors such as stress, which can weaken the immune response and promote the development of inflammatory processes.
Diagnosis of this disease
Diagnosis of pigmented villous synovitis involves a comprehensive approach that takes into account clinical symptoms, laboratory tests, and imaging techniques. The main symptoms of this disease may include:
- Joint pain that gets worse with movement.
- Swelling and redness around the affected joint.
- Limited joint mobility.
- Temperature changes in the joint area (hyperemia, sometimes hypothermia).
Laboratory tests may include complete blood counts, inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Radiological tests, including MRI and ultrasound, can visualize the joints and detect changes in the synovial membrane. It is important to differentiate from other forms of arthritis and synovitis, such as infectious or traumatic synovitis.
Treatment
Treatment of pigmented villous synovitis requires a comprehensive approach and may include pharmacological, surgical and non-pharmacological methods. General treatment usually includes:
- The need for lifestyle changes, including physical therapy.
- Use of nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain.
Pharmacological treatment may also include immunomodulatory drugs and corticosteroids to control inflammation. In some cases, when conservative treatments do not lead to improvement, surgical intervention such as artheroscopy to remove excess synovial tissue may need to be considered. Other treatments may include physical therapy and alternative medicine such as acupuncture.
List of medications used to treat this disease
Various medications are used to treat pigmented villous synovitis, including:
- Ibuprofen (NSAID)
- Naproxen (NSAID)
- Methotrexate (immunosuppressant)
- Corticosteroids such as prednisolone
- Ketorolac (analgesic)
- Sertiolone and Kitupred tablets (a group of slow-acting anti-inflammatory drugs)
Each drug has its own indications and contraindications, so it should be prescribed under strict medical supervision.
Disease monitoring
Monitoring the condition of a patient with pigmented villous synovitis is important to assess the effectiveness of the treatment and timely detection of possible complications. Control stages include:
- Regular check-ups with a specialist to assess clinical status.
- Laboratory tests to monitor levels of inflammatory markers.
- Radiological examinations to assess the structure of joints and identify possible degenerative changes.
The prognosis with adequate and timely treatment is usually favorable, but complications such as persistent pain, limited joint mobility and the development of osteoarthritis are possible.
Age-related features of the disease
Pigmented villous synovitis may manifest itself differently depending on the patient's age group. In young people, the disease often develops suddenly and may be associated with injuries. In adulthood, PVS usually has a more chronic course with periods of exacerbation and remission. Older patients are more likely to encounter concomitant diseases, which can complicate diagnosis and treatment. It is important to take age-related features into account when developing an individual treatment regimen.
Questions and Answers
- What are the main symptoms of pigmented villous synovitis? The main symptoms include joint pain, swelling, limited mobility and temperature changes in the area of the affected joint.
- How is pigmented villous synovitis diagnosed? Diagnosis includes clinical symptoms, laboratory tests, radiological examinations and differential diagnosis with other forms of arthritis.
- What is the treatment for pigmented villous synovitis? Treatment may include nonsteroidal anti-inflammatory drugs, immunomodulators, surgical methods, and physical therapy.
- Does age affect the course of the disease? Yes, the disease can manifest itself differently depending on the patient's age, including time of onset, severity, and comorbidities.
- What is the prognosis for patients with pigmented villous synovitis? The prognosis is usually good with proper treatment, but complications may occur that require additional monitoring.
